

Nomination committee in Oasmia for the 2020 AGM

In accordance with the decision at the Annual General Meeting of Oasmia Pharmaceutical AB on September 26, 2019, the two largest shareholders in terms of voting rights have chosen to participate in the Nomination Committee. Together with the Chairman of the Board they will constitute the Nomination Committee for the 2020 Annual General Meeting.

Representatives:

Per Arwidsson, Arwidstro, Chairman of the Nomination Committee

Håkan Lagerberg

and Jörgen Olsson, Chairman of the Board

The Annual General Meeting for Oasmia will be held in Uppsala on Wednesday September 9, 2019. Shareholders who wish to submit proposals regarding the Board of Directors, the Chairman of the Board, remuneration for the Board, Chairman for the AGM or the Nomination Committee for the next Annual General Meeting can contact Oasmia's Chairman via e-mail: nomination@oasmia.com.

For further information, please contact
Urban Ekelund
Investor Relations Oasmia
e-mail: IR@Oasmia.com

About Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company's product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Stockholm and Frankfurt Stock Exchange.

For more information:

Urban Ekelund, IR Manager Oasmia
Phone: +46 18-50 54 40
E-mail: IR@oasmia.com

About Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB develops, manufactures, markets and sells an improved generation of drugs within human and veterinary oncology. Product development aims to produce novel formulations of well-established cytostatic agents which show improved performance, an improved side-effect profile and a wider range of therapeutic areas compared with existing alternatives. Product development is based on the proprietary technology platform XR17. Oasmia has been successful in driving its first product candidate, Apealea (paclitaxel micellar), through clinical development, and has applied for and achieved market approval in the European Union and other territories. Oasmia is in the process of transitioning into the commercialization phase of the product Apealea and making the product accessible to patients.

Attachments

[Nomination committee in Oasmia for the 2020 AGM](#)